Published in Cancer Res on December 01, 2010
Stable isotope-resolved metabolomics and applications for drug development. Pharmacol Ther (2011) 1.29
Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies. Drug Des Devel Ther (2013) 0.88
Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia. AAPS J (2013) 0.83
GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cells. Int J Nanomedicine (2015) 0.80
Luciferase does not Alter Metabolism in Cancer Cells. Metabolomics (2014) 0.79
Influence of bioluminescence imaging dynamics by D-luciferin uptake and efflux mechanisms. Mol Imaging (2012) 0.78
Non-Invasive In Vivo Imaging and Quantification of Tumor Growth and Metastasis in Rats Using Cells Expressing Far-Red Fluorescence Protein. PLoS One (2015) 0.76
DDMC-p53 gene therapy with or without cisplatin and microwave ablation. Onco Targets Ther (2015) 0.75
A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging. PLoS One (2017) 0.75
High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer (2004) 5.99
Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev (1993) 3.58
A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods (2008) 3.31
Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia (2001) 2.97
Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis (2003) 2.90
Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques (2007) 1.66
Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol Imaging (2004) 1.65
Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging (2008) 1.46
Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS One (2009) 1.37
Quantitative bioluminescence imaging of transgene expression in vivo. Anal Biochem (2006) 1.21
A quantitative study of factors affecting in vivo bioluminescence imaging. Luminescence (2008) 1.19
APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell Biochem (2008) 1.18
The expression level of luciferase within tumour cells can alter tumour growth upon in vivo bioluminescence imaging. Luminescence (2007) 0.94
Noninvasive in vivo whole body luminescent analysis of luciferase labelled orthotopic prostate tumours. Eur J Cancer (2004) 0.83
New insights into mechanism and regulation of actin capping protein. Int Rev Cell Mol Biol (2008) 2.11
Myo1c binds phosphoinositides through a putative pleckstrin homology domain. Mol Biol Cell (2006) 1.74
Unusual kinetic and structural properties control rapid assembly and turnover of actin in the parasite Toxoplasma gondii. Mol Biol Cell (2005) 1.50
A multiscale model linking ion-channel molecular dynamics and electrostatics to the cardiac action potential. Proc Natl Acad Sci U S A (2009) 1.43
Overlapping and distinct functions for cofilin, coronin and Aip1 in actin dynamics in vivo. J Cell Sci (2010) 1.35
Dinitroanilines bind alpha-tubulin to disrupt microtubules. Mol Biol Cell (2004) 1.34
Structure/function analysis of the interaction of phosphatidylinositol 4,5-bisphosphate with actin-capping protein: implications for how capping protein binds the actin filament. J Biol Chem (2006) 1.30
An epilepsy/dyskinesia-associated mutation enhances BK channel activation by potentiating Ca2+ sensing. Neuron (2010) 1.30
The kinetics of cooperative cofilin binding reveals two states of the cofilin-actin filament. Biophys J (2010) 1.24
Taxol allosterically alters the dynamics of the tubulin dimer and increases the flexibility of microtubules. Biophys J (2008) 1.24
Neurodegeneration mutations in dynactin impair dynein-dependent nuclear migration. Proc Natl Acad Sci U S A (2009) 1.23
Evolutionarily divergent, unstable filamentous actin is essential for gliding motility in apicomplexan parasites. PLoS Pathog (2011) 1.22
Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magn Reson Med (2008) 1.19
Nucleotide effects on the structure and dynamics of actin. Biophys J (2007) 1.18
An actin-filament-binding interface on the Arp2/3 complex is critical for nucleation and branch stability. Proc Natl Acad Sci U S A (2010) 1.13
Label-free photoacoustic microscopy of myocardial sheet architecture. J Biomed Opt (2012) 1.11
Mapping the cofilin binding site on yeast G-actin by chemical cross-linking. J Mol Biol (2008) 1.09
Binding of myotrophin/V-1 to actin-capping protein: implications for how capping protein binds to the filament barbed end. J Biol Chem (2006) 1.09
An actin cytoskeleton with evolutionarily conserved functions in the absence of canonical actin-binding proteins. Proc Natl Acad Sci U S A (2011) 1.05
A genetic dissection of Aip1p's interactions leads to a model for Aip1p-cofilin cooperative activities. Mol Biol Cell (2006) 1.04
Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin. Biochemistry (2004) 1.04
Multivariate analyses of amyloid-beta oligomer populations indicate a connection between pore formation and cytotoxicity. PLoS One (2012) 1.02
The unusual dynamics of parasite actin result from isodesmic polymerization. Nat Commun (2013) 1.01
The interaction of capping protein with the barbed end of the actin filament. J Mol Biol (2010) 1.00
Mathematical modeling of cell migration. Methods Cell Biol (2008) 0.98
Effects of solution crowding on actin polymerization reveal the energetic basis for nucleotide-dependent filament stability. J Mol Biol (2008) 0.93
F-actin structure destabilization and DNase I binding loop: fluctuations mutational cross-linking and electron microscopy analysis of loop states and effects on F-actin. J Mol Biol (2009) 0.92
The NH2 terminus of RCK1 domain regulates Ca2+-dependent BK(Ca) channel gating. J Gen Physiol (2005) 0.92
Mechanism for CARMIL protein inhibition of heterodimeric actin-capping protein. J Biol Chem (2012) 0.91
Binding and interaction of dinitroanilines with apicomplexan and kinetoplastid alpha-tubulin. J Med Chem (2006) 0.90
Quantifying the evolution of vascular barrier disruption in advanced atherosclerosis with semipermeant nanoparticle contrast agents. PLoS One (2011) 0.90
Single-particle characterization of Aβ oligomers in solution. ACS Nano (2012) 0.90
Improved signal processing to detect cancer by ultrasonic molecular imaging of targeted nanoparticles. J Acoust Soc Am (2011) 0.90
Mechanical properties of doubly stabilized microtubule filaments. Biophys J (2013) 0.89
Mutations in alpha-tubulin confer dinitroaniline resistance at a cost to microtubule function. Mol Biol Cell (2007) 0.88
Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field. J Law Med Ethics (2012) 0.87
Energetics and dynamics of constrained actin filament bundling. Biophys J (2006) 0.87
A model for the interfacial kinetics of phospholipase D activity on long-chain lipids. Biophys J (2013) 0.87
Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.86
Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. J Biol Chem (2013) 0.85
Protein-protein interactions: making drug design second nature. Nat Chem (2009) 0.84
Thrombin-inhibiting nanoparticles rapidly constitute versatile and detectable anticlotting surfaces. Nanotechnology (2014) 0.84
Nanomedicine opportunities in cardiology. Ann N Y Acad Sci (2006) 0.82
The interaction of cofilin with the actin filament. J Mol Biol (2011) 0.81
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. Antimicrob Agents Chemother (2010) 0.81
Drug-like leads for steric discrimination between substrate and inhibitors of human acetylcholinesterase. Chem Biol Drug Des (2011) 0.81
First-contact time to a patch in a multidimensional potential well. Phys Rev E Stat Nonlin Soft Matter Phys (2007) 0.80
Synthetic chondramide A analogues stabilize filamentous actin and block invasion by Toxoplasma gondii. J Nat Prod (2013) 0.79
Molecular modeling of the cytoskeleton. Methods Cell Biol (2008) 0.78
The basic concepts of molecular modeling. Methods Enzymol (2009) 0.78
Microtubules: sizing up the GTP cap. Curr Biol (2012) 0.76
Synthesis of chondramide A analogues with modified β-tyrosine and their biological evaluation. Chemistry (2011) 0.76
Eruptive Melanocytic Acral Nevi in the Setting of 6-mercaptopurine Therapy. J Drugs Dermatol (2017) 0.75